NCCN testing guidelines have long been a key tool that payers use to decide which cancer patients will be covered for genetic testing. With the rapid growth of precision medicine, it has become more important than ever to ensure every patient that should be tested is tested, raising new questions about how effectively and consistently current guidelines are applied. Dr. Peter Beitsch addresses some of those questions in a recent study published by the Journal of Clinical Oncology and many are saying will have a major impact on women with breast cancer in the future. Listen to the full episode here.

</